Sodium hydride → Nevirapine
반응식
Cl[C:2]1[C:7]([NH:8][C:9]([C:11]2[C:12]([NH:17][CH:18]3[CH2:20][CH2:19]3)=[N:13][CH:14]=[CH:15][CH:16]=2)=[O:10])=[C:6]([CH3:21])[CH:5]=[CH:4][N:3]=1.[H-].[Na+]>>[CH3:21][C:6]1[CH:5]=[CH:4][N:3]=[C:2]2[N:17]([CH:18]3[CH2:20][CH2:19]3)[C:12]3[N:13]=[CH:14][CH:15]=[CH:16][C:11]=3[C:9](=[O:10])[NH:8][C:7]=12참가 물질
3
실험 절차
3-Amino-2-chloro-4-methylpyridine of Formula A is condensed with 2-chloronicotinoyl chloride of Formula B to give 2-chloro-N-(2-chloro-4-methyl-3-pyridinyl)-3-pyridine carboxamide of Formula II, which is then reacted with cyclopropylamine to give N-(2-chloro-4-methyl-3-pyridyl)-2 -cyclopropylamino) -3-pyridine carboxamide of Formula III. Then N-(2-chloro-4-methyl-3-pyridyl)-2-(cyclopropylamino)-3-pyridine carboxamide was cyclized in the presence of sodium hydride to give nevirapine of Formula I. The disadvantage of the above process is use of large excess of cyclopropylamine. Further, with the above process undesirable side products are obtained during the reaction, which makes the product impure.
출처 및 근거
- ORD 기록
- ord-90d4f3b97de947d29991dfbc385bd571
- 출처 데이터셋
- uspto-grants-2012_07
- 특허 번호
- US08212025B2
반응 노트
불러오는 중…